Cargando…

Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia

BACKGROUND: The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. METHODS: Data from 3556 patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chul-Hee, Han, Kyung-Ah, Oh, Han-Jin, Tan, Kevin Eng-Kiat, Sothiratnam, Radhakrishna, Tjokroprawiro, Askandar, Klein, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549486/
https://www.ncbi.nlm.nih.gov/pubmed/22742083
http://dx.doi.org/10.1111/j.1753-0407.2012.00220.x
Descripción
Sumario:BACKGROUND: The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. METHODS: Data from 3556 patients treated with once-daily MXR for 12 weeks, or until discontinuation, were analyzed. RESULTS: Treatment with MXR was well tolerated, with 97.4% of patients completing 12 weeks of treatment. Only 3.3% of patients experienced one or more gastrointestinal (GI) side-effects and only 0.7% of patients discontinued for this reason (primary endpoint). The incidence of GI side-effects and related discontinuations appeared to be considerably lower during short-term MXR therapy than during previous treatment (mean 2.71 years’ duration), most commonly with immediate-release metformin. A 12-week course of MXR therapy also reduced HbA1c and fasting glucose levels from baseline. CONCLUSIONS: The present study provides new insights into the incidence of GI side-effects with MXR in Asian patients with T2DM and on the tolerability of MXR in non-Caucasian populations. Specifically, these data indicate that once-daily MXR not only improves measures of glycemic control in Asian patients with T2DM, but also has a favorable GI tolerability profile that may help promote enhanced adherence to oral antidiabetic therapy.